Atara Biotherapeutics, Inc. (ATRA)

NASDAQ: ATRA · IEX Real-Time Price · USD

7.52

-0.84 (-10.05%)

At close: Jul 2, 2024, 4:00 PM

7.50

-0.02 (-0.27%)

After-hours: Jul 2, 2024, 7:03 PM EDT

Atara Biotherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018 - 2014
Market Capitalization	37	52	311	1,393	1,526	892	Upgrade
Market Cap Growth	-70.22%	-83.21%	-77.67%	-8.66%	71.05%	-43.76%	Upgrade
Enterprise Value	68	81	157	1,048	1,038	647	Upgrade
PE Ratio	-	-0.19	-1.36	-4.10	-4.97	-3.06	Upgrade
PS Ratio	1.06	6.10	4.89	68.51	-	-	Upgrade
PB Ratio	-0.84	-0.53	2.46	4.98	3.30	3.07	Upgrade
P/FCF Ratio	-0.45	-0.27	-1.73	-6.03	-8.23	-3.70	Upgrade
P/OCF Ratio	-0.45	-0.27	-1.15	-6.32	-8.44	-3.79	Upgrade
EV/Sales Ratio	1.97	9.41	2.46	51.51	-	-	Upgrade
EV/EBITDA Ratio	-0.54	-0.32	-0.73	-3.18	-3.47	-2.25	Upgrade
EV/EBIT Ratio	-0.50	-0.30	-0.69	-3.08	-3.36	-2.19	Upgrade
EV/FCF Ratio	-0.62	-0.42	-0.87	-4.53	-5.60	-2.68	Upgrade
Debt / Equity Ratio	-0.79	-0.81	0.70	0.09	0.03	0.05	Upgrade
Debt / EBITDA Ratio	-0.37	-0.32	-0.41	-0.08	-0.04	-0.05	Upgrade
Debt / FCF Ratio	-0.42	-0.41	-0.49	-0.11	-0.07	-0.06	Upgrade
Quick Ratio	0.46	0.60	3.59	3.52	6.06	7.06	Upgrade
Current Ratio	0.59	0.72	3.74	3.64	6.31	7.43	Upgrade
Asset Turnover	0.18	0.04	0.16	0.04	0	0	Upgrade
Interest Coverage	-44.69	-51.24	-611.04	-	-	-	Upgrade
Return on Equity (ROE)	387.00%	1422.30%	-114.80%	-103.00%	-84.60%	-103.40%	Upgrade
Return on Assets (ROA)	-121.70%	-122.30%	-57.90%	-71.40%	-71.30%	-89.10%	Upgrade
Return on Capital (ROIC)	1130.76%	1459.19%	-130.51%	-111.58%	-65.01%	-96.97%	Upgrade
Earnings Yield	-632.07%	-528.31%	-73.36%	-24.41%	-20.10%	-32.63%	Upgrade
FCF Yield	-501.86%	-371.51%	-57.79%	-16.58%	-12.14%	-27.04%	Upgrade
Buyback Yield / Dilution	-35.22%	-3.85%	-8.88%	-26.63%	-44.17%	-17.11%	Upgrade
Total Shareholder Return	-35.22%	-3.85%	-8.88%	-26.63%	-44.17%	-17.11%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).